October 10, 2020 04:16 am | Updated 04:16 am IST
A test tube labeled with the vaccine is seen in front of AstraZeneca logo in this illustration taken, September 9, 2020.
U.S. Department of Health and Human Services on Friday signed an agreement with AstraZeneca Plc for development and supply of the company's COVID-19 antibody treatment, a cocktail of two monoclonal antibodies - similar class of drugs that was administered to President Donald Trump.
The agency will provide nearly $486 million to AstraZeneca for two Phase 3 clinical trials as well as a large-scale manufacturing demonstration project and supply of AZD7442 doses in the United States.
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.
